A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain

Condition:   HIV-1 Interventions:   Drug: D/C/F/TAF FDC;   Drug: TAF/FTC FDC;   Drug: INI Based Regimen Sponsor:   Janssen Scientific Affairs, LLC Not yet recruiting

Source: ClinicalTrials.gov - June 23, 2020 Category: Research Source Type: clinical trials